Evidence map›Paper›PMID 39359442›Full record

ArticleCaspian journal of internal medicine2024

Immunohistochemical markers in predicting behavior of bladder urothelial carcinoma.

Simin Torabi Nezhad, Leila Malekmakan, Mina Mashayekh, Nazanin Karamifar, Taraneh Tadayon

Abstract read
In one paragraph

Article in Caspian journal of internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Simin Torabi NezhadShiraz Nephro-urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Leila MalekmakanShiraz Nephro-urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mina MashayekhShiraz Nephro-urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Nazanin KaramifarSattarkhan Street, Dena Hospital, Shiraz, Iran.
Taraneh TadayonShiraz Nephro-urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Bladder cancer is the 5 Methods: In this study, we reassessed the specs of proven UC among Iranian patients. Sixty specimens were collected, contained of 30 low grade and 30 high grade urothelial carcinomas. All slides were assessed by immunohistochemistry study for p21, p27, Her-2/ Results: We evaluated 60 patients in this study with mean age of 66±11 years and majority of them are men. High expression of p27 showed significant correlation with LGUC ( Conclusion: In the present study, CD10 intensity is the only marker that directly predicts the prognosis. The higher intensity leads to poor prognosis (recurrence or metastasis). More studies must be done in this aspect to resolve the controversies and clarify the role of immunohistochemical markers in predicting BC behaviors.

Indexed as

Bladder cancer; p21 cell cycle regulator; p27 CDK inhibitor; HER-2 Proto-Oncogene Protein; CD10 antigen

Identifiers

PMID39359442
PMCPMC11444117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.